Lexeo Therapeutics, Inc. — Director's Dealing 2025

Apr 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lexeo Therapeutics, Inc. (LXEO)
CIK: 0001907108
Period of Report: 2025-03-14

Reporting Person: Robertson Jenny (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-14	Common Stock	A	5720	$2.61	Acquired	63619	Direct

Footnotes

F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

F2: Includes 54,062 restricted stock units.